Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5609230 | 1.00 | EPHX1 (0.66) | EPHX1ALDH1A1CYP1A2TDP1RAD52 | |
| SCHEMBL5608421 | 0.95 | EPHX1 (0.59) | EPHX1ALDH1A1 | |
| SCHEMBL859151 | 0.93 | EPHX1 (0.78) | EPHX1ALDH1A1CYP1A2TDP1RAD52 | |
| SCHEMBL5609735 | 0.93 | EPHX1 (0.78) | EPHX1ALDH1A1CYP1A2TDP1RAD52 | |
| SCHEMBL3430826 | 0.93 | EPHX1 (0.78) | EPHX1ALDH1A1CYP1A2TDP1RAD52 | |
| SCHEMBL9263734 | 0.89 | EPHX1 (0.71) | EPHX1ALDH1A1CYP1A2TDP1RAD52 | |
| SCHEMBL17255663 | 0.87 | EPHX1 (0.62) | EPHX1ALDH1A1CYP1A2 | |
| SCHEMBL3854176 | 0.85 | EPHX1 (0.66) | EPHX1ALDH1A1CYP1A2TDP1 | |
| SCHEMBL1628137 | 0.85 | EPHX1 (0.66) | EPHX1ALDH1A1 | |
| SCHEMBL6050812 | 0.85 | ALDH1A1 (0.63) | EPHX1ALDH1A1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101732711-A | Preparation of nose-spraying flu immunization pentavalent or multivalent inactivated vaccine and application thereof | INST MICROBIOLOGY & EPIDEMIOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA | 2010-06-16 | — | — | CN | claimed |
| US-20240108683-A1 | Method for Side Effect Reduction in the Use of Statins Via Physiologically Synthesized Glutathione | PROIMMUNE CO LLC (US) | 2024-04-04 | — | — | US | disclosed |
| EP-3193824-B1 | A COMPOSITION FOR USE IN TREATING HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA VIA PHYSIOLOGICALLY SYNTHESISED GLUTATHIONE | THE PROIMMUNE COMPANY LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3154547-B1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-114269719-A | Urea derivatives as CB1 allosteric modulators | RTI国际 | 2022-04-01 | — | — | CN | disclosed |
| US-20220047504-A1 | ORAL DISSOLVABLE FILM WITH PORES EXTENDING THERETHROUGH | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220023198-A1 | ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATE | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11179331-B1 | Oral soluble film containing sildenafil citrate | CURE PHARMACEUTCAI HOLDING CORP (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210322306-A1 | ORAL DISSOLVABLE FILM WITH HIGH LOAD OF POLYMERIC BINDER | CURE PHARMACEUTICAL HOLDING CORP. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3829566-A2 | COMPOSITIONS AND METHODS FOR TREATING THE EYE | Johnson & Johnson Surgical Vision, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20070025948-A1 | Dilution-type sterilizer composition | DAINIPPON SUMITOMO PHARMA CO. LTD (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20060034871-A1 | Immunogenic compositions for Chlamydia trachomatis | CHIRON CORPORATION (US) | 2006-02-16 | — | — | US | disclosed |
| US-20050222168-A1 | Beta-carboline derived guanidine alkaloids, tiruchenduramine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-10-06 | — | — | US | disclosed |
| US-20050221415-A1 | Method of assay with sulfonic acid compound and nitro compound | ARKRAY, INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1556023-A1 | NUTRITIONAL OR THERAPEUTIC COMPOSITIONS | Crum, Albert B. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1531855-A2 | TREATMENT OF BONE DISORDERS WITH SKELETAL ANABOLIC DRUGS | Osteotrophin LLC (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004026289-A1 | NUTRITIONAL OR THERAPEUTIC COMPOSITIONS | THE PROIMMUNE COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2003059291-A2 | TREATMENT OF BONE DISORDERS WITH SKELETAL ANABOLIC DRUGS | OSTEOTROPHIN LLC (US) | 2003-07-24 | — | — | WO | disclosed |
| US-6592908-B1 | Nutritional or therapeutic compositions | CRUM ALBERT (US) | 2003-07-15 | — | — | US | disclosed |
| CN-1370173-A | Isomeric fused pyrrolocarbazoles and isotetralones | CEPHALON INC (US) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070025948-A1 | Dilution-type sterilizer composition | HAO2, ALPG, CHCHD6 | EPHX1 3557/4885ALDH1A1 602/4885CYP1A2 422/4885 |
| US-20220023198-A1 | ORAL SOLUBLE FILM CONTAINING SILDENAFIL CITRATE | PDE12, SORD, PDE5A | EPHX1 1408/4885ALDH1A1 302/4885CYP1A2 795/4885 |
| US-20050222168-A1 | Beta-carboline derived guanidine alkaloids, tiruchenduramine | GANAB, GBA3, TREH | EPHX1 2837/4885ALDH1A1 927/4885CYP1A2 3538/4885 |
| US-11179331-B1 | Oral soluble film containing sildenafil citrate | PDE12, SORD, PDE5A | EPHX1 1408/4885ALDH1A1 302/4885CYP1A2 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.